The estimated Net Worth of Alistair Milnes is at least 2.09 百万$ dollars as of 3 July 2024. Mr Milnes owns over 967 units of Bicycle Therapeutics plc stock worth over 1,921,547$ and over the last 3 years he sold BCYC stock worth over 169,916$.
Mr has made over 8 trades of the Bicycle Therapeutics plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 967 units of BCYC stock worth 18,992$ on 3 July 2024.
The largest trade he's ever made was exercising 5,155 units of Bicycle Therapeutics plc stock on 25 March 2022 worth over 103,719$. On average, Mr trades about 1,429 units every 92 days since 2022. As of 3 July 2024 he still owns at least 71,274 units of Bicycle Therapeutics plc stock.
You can see the complete history of Mr Milnes stock trades at the bottom of the page.
Alistair Milnes is the Chief Operating Officer at Bicycle Therapeutics plc.
Alistair's mailing address filed with the SEC is C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0, CB21 6GS.
Over the last 5 years, insiders at Bicycle Therapeutics plc have traded over 10,024,476$ worth of Bicycle Therapeutics plc stock and bought 3,275,775 units worth 45,860,850$ . The most active insiders traders include Plc Gsk、Bros. Advisors Lp667, L.P.B...、Bioventures Ltd Novartis Ag.... On average, Bicycle Therapeutics plc executives and independent directors trade stock every 19 days with the average trade being worth of 1,155,236$. The most recent stock trade was executed by Michael Charles Ferguson Ha... on 3 July 2024, trading 246 units of BCYC stock currently worth 4,831$.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics plc executives and other stock owners filed with the SEC include: